This bulletin has been updated to include a number of additional items, and is now concurrent with the latest evidence. In addition to the bulletin, a 2 page briefing has been produced, highlighting the top 10 therapeutic areas to focus on, based on the clinical and cost risk of continuing therapy based on maintenance doses if it is not possible to do a full multidisciplinary medicines review.
